Adapting the power of density gradient separations for characterizing viral vector fullness
On demand

Adapting the power of density gradient separations for characterizing viral vector fullness

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Adapting the power of density gradient separations for characterizing viral vector fullness

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

Density gradient ultracentrifugation (DGUC) has long been a staple technology providing high resolution purification of numerous materials used in vaccines, gene therapy, and other advanced therapeutics. While traditionally used for purification, this approach has recently been adapted for analytical purposes supporting advanced therapies by using an analytical ultracentrifuge (AUC), such as the Optima AUC. Density gradient equilibrium AUC (DGE-AUC) is a highly simplified analytical method that provides the same high-resolution benefits as its prep-scale counterpart, along with numerous advantages over the current gold standard sedimentation velocity AUC (SV-AUC) method. DGE-AUC with CsCl gradients is amenable to AAV, adenovirus, and other large viral particles, providing high resolution data with significantly less sample (>30X sensitivity) than SV-AUC and readily enables the use of multi-wavelength analysis without compromising data quality. Furthermore, DGE-AUC is serotype-agnostic with intuitive interpretation and analysis (not requiring specialized AUC software), poised to benefit a wide array of gene therapy & viral vector users where traditional analytical methods fall short.

Watch this webinar to learn:

  • Adapting gold standard CsCl isopycnic density gradient purification methods to AUC
  • Advantages of DGE-AUC over “classical” methods:

Highly simplified interpretation and analysis – a walkthrough with Excel

Higher resolution with significantly less sample

  • Applications of DGE-AUC in gene therapy and beyond: AAV, adenovirus, plasmids
Shawn Sternisha PhD
Shawn Sternisha PhD
Shawn Sternisha is currently a Senior Field Applications Scientist in the Biotechnology Business Unit at Beckman Coulter Life Sciences where he develops applications and supports centrifuge product lines. Shawn attended Illinois State University for his undergraduate studies and went on to earn his Ph.D. in Biochemistry at Florida State University. His doctoral research was focused on understanding how glucokinase regulates glucose homeostasis at the molecular level. Shawn has also previously worked at GlaxoSmithKline where he was involved in investigating novel imaging modalities for monitoring mammalian cell cultures. Shawn is broadly interested in enzyme structure-function relationships and mechanisms of action, cell and gene therapy, and expanding applications of biochemical and biophysical techniques (namely Analytical Ultracentrifugation). Shawn currently resides in Miami, FL with his fiancée Patty and their dog Ruby. In his free time, he enjoys cooking, running, traveling, and learning Spanish.